ClinicalTrials.gg
CompletedNCT03334877Updated Nov 8, 2017

Prediction of Preterm Labor in Asymptomatic High Risk Women

An observational study in Preterm Labor, sponsored by Zagazig University. Completed. Open to female participants aged 18 Years to 34 Years. Per ClinicalTrials.gov, last updated 2017-11-08.

Sponsored by Zagazig University · Observational

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
220
Ages
18 Years to 34 Years
Sex
Female
01

Study summary

Two hundred and twenty women with singleton pregnancies and risk factors for spontaneous preterm birth were included in this study. Cervico vaginal fluid sampling was undertaken for qualitative assessment of β -human chorionic gonadotropin (β-hCG) and fetal fibronectin(fFN)at 24 weeks of gestation.

For qualitative assay of both b-hCG and fFN, first vaginal specimens were collected by the following method:

Specimen collection

A sterile Cusco speculum was introduced into the vagina; the anterior lip of the cervix was grasped with sponge forceps and a cotton-tipped swab was placed into the external part of the endocervical canal (not reaching the internal os) and then into the posterior fornix (each for at least 1 min) to obtain an adequate sample of cervico vaginal secretions. Sampling was performed before doing any cervical manipulation (digital or ultrasound examination) and before introducing any vaginal material (lubricants or medications). The Hologic Specimen Collection Kit is the only acceptable specimen collection system which can be used to collect specimens for this assay. The polyester tipped swab provided in the Specimen Collection Kit should be inserted into the vagina and lightly rotated across the posterior fornix for approximately 10 seconds to absorb the cervico vaginal secretions. Once the specimen is obtained, carefully remove the swab from the vagina and place it into the tube of buffer provided with the Specimen Collection Kit. Two Specimen Collection Device per patient were obtained; one for each assay. Label the Specimen Transport Tubes with the patient's name and any other identifying information required.

All women were then followed up till delivery. Women were categorized into two arms: women who delivered preterm (before 37 completed weeks of gestation) and women who delivered at term (after 37 completed weeks of gestation).

Read the detailed description

Patients and methods

This prospective observational study was undertaken from May 2015to October 2017 at Zagazig university hospitals.This study was approved by the Research Ethical Committee of Zagazig university hospital. Written informed consent was obtained from all participants. Two hundred and twenty women with singleton pregnancies and risk factors for spontaneous preterm birth were included in this study. Cervico vaginal fluid sampling was undertaken for qualitative assessment of β -human chorionic gonadotropin (β-hCG) and fetal fibronectin (fFN) at 24 weeks of gestation.

Inclusion criteria:

There were past history of one or more spontaneous preterm labor or preterm rupture of membranes at less than 37 weeks of gestation, previous spontaneous second trimester miscarriage, previous cervical surgery (large loop excision of the transformation zone, loop electro surgical excision procedure, laser or cone excision), or an accidental finding of a cervical length of 25 mm or less in the current pregnancy.

Exclusion criteria:

Women who reported prior sexual intercourse (within 24 hours), or confirmed or suspected rupture of membranes, or who had vaginal bleeding visible on the swab.

Gestational age was confirmed by early obstetric ultrasonography (11-14 weeks of gestation). Participant baseline demographic data, obstetric history, and risk factors were tabulated and analysed.

For qualitative assay of both b-hCG and fFN, first vaginal specimens were collected by the following method:

Specimen collection

A sterile Cusco speculum was introduced into the vagina; the anterior lip of the cervix was grasped with sponge forceps and a cotton-tipped swab was placed into the external part of the endocervical canal (not reaching the internal os) and then into the posterior fornix (each for at least 1 min) to obtain an adequate sample of cervico vaginal secretions. Sampling was performed before doing any cervical manipulation (digital or ultrasound examination) and before introducing any vaginal material (lubricants or medications). The Hologic Specimen Collection Kit is the only acceptable specimen collection system which can be used to collect specimens for this assay. The polyester tipped swab provided in the Specimen Collection Kit should be inserted into the vagina and lightly rotated across the posterior fornix for approximately 10 seconds to absorb the cervico vaginal secretions. Once the specimen is obtained, carefully remove the swab from the vagina and place it into the tube of buffer provided with the Specimen Collection Kit. Two Specimen Collection Device per patient were obtained; one for each assay. Label the Specimen Transport Tubes with the patient's name and any other identifying information required.

Qualitative assessment of β-hCG assessment

The qualitative assay of β-hCGwas performed as a bedside test. The swab was then inserted in a tube containing 0.75 ml of sterile normal saline for dilution. From this sample, three drops were used for a bedside HCG test using ACON-HCG one-step pregnancy test strip (Rapid diagnostic Pvt. Ltd, India). with a detection cut-off value of 25 mIU/ ML.

Qualitative assessment of fFNtest:

It was done using Quick Check fFN test; it is a 10-minute, one-step, visual test. The test strip was removed from the foil pouch and its lower end (indicated by the arrows) was inserted into the tube containing the extraction buffer for 10 minutes. A positive sample contain fFN will result in two lines in test strip and a negative sample will result in one control line in test strip.

All women were then followed up till delivery. Women were categorized into two arms: women who delivered preterm (before 37 completed weeks of gestation) and women who delivered at term (after 37 completed weeks of gestation).

Those women who had iatrogenic preterm labor due to fetal or maternal indications were excluded from the final statistical analysis and were calculated among the women who did not complete follow up. Only women with spontaneous preterm labor were included.

Pregnancy outcome details were obtained from handheld notes, reviewed by trained research midwives, and entered onto the study database. Data entry was checked for inaccuracies contemporaneously by senior research midwives. Women were considered to have the outcome of interest (spontaneous preterm birth) if they had spontaneous onset of labor, or experienced preterm premature rupture of membranes with subsequent premature delivery

02

Conditions studied

  • Preterm Labor
03

In context

Obstetric Labor, Premature

261 studies on the registry are indexed under Obstetric Labor, Premature; 38 are open to participants now.

This study's enrollment of 220 is above the median of 126 across 88 observational studies indexed under Obstetric Labor, Premature.

Browse Obstetric Labor, Premature studies →

Lead sponsor

Zagazig University is the lead sponsor of 457 studies on the registry; 77 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 34 Years
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Two hundred and twenty women with singleton pregnancies and risk factors for spontaneous preterm birth were included in this study at 24 weeks of gestation.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • There were past history of one or more spontaneous preterm labor or preterm rupture of membranes at less than 37 weeks of gestation.
  • previous spontaneous second trimester miscarriage.
  • previous cervical surgery (large loop excision of the transformation zone, loop electrosurgical excision procedure, laser or cone excision).
  • accidental finding of a cervical length of 25 mm or less in the current pregnancy.

Exclusion criteria

Exclusion Criteria:

  • Women who reported prior sexual intercourse (within 24 hours).
  • confirmed or suspected rupture of membranes.
  • vaginal bleeding visible on the swab.
05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
220 participants (actual)
Patient registry
No

Groups and cohorts

  • β -human chorionic gonadotropin

    Cervico vaginal fluid sampling was undertaken for qualitative assessment of β -human chorionic gonadotropin (β-hCG) and fetal fibronectin(fFN) at 24 weeks of gestation to predict preterm labour in asymptomatic high risk patients

    Diagnostic Test: β -human chorionic gonadotropin

Interventions

  • Diagnostic testβ -human chorionic gonadotropin

    Cervico vaginal fluid sampling was undertaken for qualitative assessment of β -human chorionic gonadotropin (β-hCG) and fetal fibronectin(fFN) at 24 weeks of gestation.

06

What researchers measure

Primary outcomes

  1. The diagnostic accuracy of qualitative level of cervico vaginal β-hCG versus fetal fibronectin

    Prediction of preterm labor in asymptomatic high risk women during antenatal care.

    Time frame: From 24 weeks gestation till delivery

07

Study locations

No study locations are listed for this record.

08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 8, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03334877
Lead sponsor
Zagazig University
Responsible party
Mohamed lotfy (assistant Professor of Obstetrics and Gynecology, Zagazig University) — Principal investigator
First posted
Nov 7, 2017
Start date
May 15, 2015
Primary completion
May 10, 2017
Completion
Oct 1, 2017
Last update
Nov 8, 2017

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion